UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 43

Sortiert nach

Efficacy of Palbociclib Combinations in Hormone Receptor–Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment

Clinical breast cancer, 2018-12, Vol.18 (6), p.e1401-e1405

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer

Journal of clinical oncology, 2000-05, Vol.18 (9), p.1921-1927

2000

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab (Pem) in metastatic castration-resistant prostate cancer (mCRPC): Experience from a comprehensive cancer center

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.113-113

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib trial of enzalutamide with oral decitabine/cedazuridine in metastatic castration-resistant prostate cancer (CRPC)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.TPS252-TPS252

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib trial of enzalutamide (Enza) with venetoclax (Ven) in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.182-182

2023

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS406-TPS406

2023

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.340-340

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2 + breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS1112-TPS1112

2023

Link zum Volltext

Verfügbarkeit prüfen

Differences in immune tumor microenvironment between primary and metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2019-03, Vol.37 (8_suppl), p.58-58

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib trial of enzalutamide with venetoclax in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS5599-TPS5599

2020

Link zum Volltext

Verfügbarkeit prüfen

Bone scan index at baseline as a tool for predicting hematologic toxicity in metastatic castration-resistant prostate cancer patients eligible for radium-223 treatment

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e16513-e16513

2017

Link zum Volltext

Verfügbarkeit prüfen

Trends in synchronous invasive ductal carcinomas of the breast: A SEER database analysis

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e13081-e13081

2017

Link zum Volltext

Verfügbarkeit prüfen

Outcome of everolimus based therapy in hormone receptor positive metastatic breast cancer patients after progression on palbociclib combination

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1064-1064

2018

Link zum Volltext

Verfügbarkeit prüfen

Interim analysis of a pilot study: Impact of high-dose, single fraction radiation on immunogenicity of sipuleucel-T in metastatic castration resistant prostate cancer patients

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e16538-e16538

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naïve metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.561-561

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase I/II trial of ketoconazole + calcitriol [1,25(OH)2D3] in castration-resistant prostate cancer

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.5065-5065

2016

Link zum Volltext

Verfügbarkeit prüfen

Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma

Clinical genitourinary cancer, 2016-02, Vol.14 (1), p.e59-e65

2016

Link zum Volltext

Verfügbarkeit prüfen

Secondary breast cancer following hematologic malignancies

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e18014-e18014

2014

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of neoadjuvant dual HER2 targeted therapy in HER2 amplified breast cancer in clinical practice: a single institutional experience

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e12096-e12096

2016

Link zum Volltext

Verfügbarkeit prüfen

Outcome of palbociclib based therapy in hormone receptor positive metastatic breast cancer patients after treatment with everolimus

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1054-1054

2017

Link zum Volltext

Verfügbarkeit prüfen

Tolerability and cardiac safety of neo/adjuvant trastuzumab-based chemotherapy regimens for HER2+ breast cancer: A single institution experience

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e11508-e11508

2013

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with capecitabine for advanced solid tumors (including patients with progressive or recurrent HER2-negative metastatic breast cancer)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3057-3057

2013

Link zum Volltext

Verfügbarkeit prüfen

Predictors of complete pathological response (pT0) to neoadjuvant chemotherapy (NAC) in muscle-invasive bladder carcinoma (MIBC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e15501-e15501

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(43)

Sprache

Englisch
(43)
Japanisch
(2)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Journal Of Clinical Oncology
(26)
Catheterization And Cardiovascular Interventions
(6)
Journal Of The American College Of Cardiology
(5)
Circulation
(3)
Cancer
(1)
Clinical Breast Cancer
(1)
Clinical Genitourinary Cancer
(1)

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy of Palbociclib Combinations in Hormone Receptor–Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment

Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer

Pembrolizumab (Pem) in metastatic castration-resistant prostate cancer (mCRPC): Experience from a comprehensive cancer center

A phase Ib trial of enzalutamide with oral decitabine/cedazuridine in metastatic castration-resistant prostate cancer (CRPC)

Phase Ib trial of enzalutamide (Enza) with venetoclax (Ven) in metastatic castration-resistant prostate cancer (mCRPC)

A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy

A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy

Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2 + breast cancer

Differences in immune tumor microenvironment between primary and metastatic castration-resistant prostate cancer

A phase Ib trial of enzalutamide with venetoclax in metastatic castration-resistant prostate cancer (mCRPC)

Bone scan index at baseline as a tool for predicting hematologic toxicity in metastatic castration-resistant prostate cancer patients eligible for radium-223 treatment

Trends in synchronous invasive ductal carcinomas of the breast: A SEER database analysis

A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma

SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691)

Outcome of everolimus based therapy in hormone receptor positive metastatic breast cancer patients after progression on palbociclib combination

Interim analysis of a pilot study: Impact of high-dose, single fraction radiation on immunogenicity of sipuleucel-T in metastatic castration resistant prostate cancer patients

A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naïve metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results

A phase I/II trial of ketoconazole + calcitriol [1,25(OH)2D3] in castration-resistant prostate cancer

Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma

Secondary breast cancer following hematologic malignancies

Outcomes of neoadjuvant dual HER2 targeted therapy in HER2 amplified breast cancer in clinical practice: a single institutional experience

Outcome of palbociclib based therapy in hormone receptor positive metastatic breast cancer patients after treatment with everolimus

Tolerability and cardiac safety of neo/adjuvant trastuzumab-based chemotherapy regimens for HER2+ breast cancer: A single institution experience

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with capecitabine for advanced solid tumors (including patients with progressive or recurrent HER2-negative metastatic breast cancer)

Predictors of complete pathological response (pT0) to neoadjuvant chemotherapy (NAC) in muscle-invasive bladder carcinoma (MIBC)

Suchergebnisse filtern